Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| ras Proteins | 13 | 2021 | 128 | 4.360 |
Why?
|
| Cell Membrane | 11 | 2020 | 666 | 3.610 |
Why?
|
| Molecular Dynamics Simulation | 10 | 2019 | 245 | 2.390 |
Why?
|
| Lipid Bilayers | 5 | 2021 | 134 | 1.990 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 6 | 2019 | 154 | 1.850 |
Why?
|
| Protein Conformation | 6 | 2019 | 881 | 0.950 |
Why?
|
| Thoracostomy | 1 | 2020 | 10 | 0.770 |
Why?
|
| Hemothorax | 1 | 2020 | 15 | 0.770 |
Why?
|
| Chest Tubes | 1 | 2020 | 23 | 0.770 |
Why?
|
| Thoracic Injuries | 1 | 2020 | 32 | 0.760 |
Why?
|
| Genes, ras | 2 | 2018 | 96 | 0.710 |
Why?
|
| Protein Domains | 2 | 2019 | 128 | 0.690 |
Why?
|
| Protein Kinases | 1 | 2020 | 209 | 0.690 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2019 | 47 | 0.680 |
Why?
|
| Protein Multimerization | 2 | 2017 | 173 | 0.680 |
Why?
|
| Catalytic Domain | 5 | 2020 | 156 | 0.650 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2016 | 18 | 0.570 |
Why?
|
| Neutrophils | 2 | 2017 | 307 | 0.520 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 196 | 0.520 |
Why?
|
| Models, Chemical | 1 | 2015 | 178 | 0.510 |
Why?
|
| Protein Binding | 6 | 2017 | 1456 | 0.470 |
Why?
|
| Computational Biology | 3 | 2017 | 528 | 0.470 |
Why?
|
| Cholic Acid | 1 | 2012 | 7 | 0.440 |
Why?
|
| Cell-Derived Microparticles | 1 | 2012 | 11 | 0.440 |
Why?
|
| Phosphorylcholine | 1 | 2012 | 28 | 0.440 |
Why?
|
| Micelles | 1 | 2012 | 47 | 0.430 |
Why?
|
| Ibuprofen | 1 | 2012 | 28 | 0.430 |
Why?
|
| Phagocytosis | 1 | 2012 | 85 | 0.430 |
Why?
|
| Positron-Emission Tomography | 2 | 2013 | 329 | 0.410 |
Why?
|
| Trauma Centers | 3 | 2021 | 116 | 0.400 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 645 | 0.400 |
Why?
|
| Binding Sites | 4 | 2020 | 1098 | 0.380 |
Why?
|
| Lymphangitis | 1 | 2010 | 1 | 0.370 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 243 | 0.370 |
Why?
|
| Phosphatidylserines | 2 | 2021 | 20 | 0.370 |
Why?
|
| Mutation | 3 | 2019 | 3968 | 0.360 |
Why?
|
| Sepsis | 1 | 2012 | 306 | 0.330 |
Why?
|
| Phosphorylation | 3 | 2020 | 1106 | 0.320 |
Why?
|
| Mutation, Missense | 2 | 2019 | 276 | 0.300 |
Why?
|
| Guanosine Triphosphate | 3 | 2017 | 38 | 0.290 |
Why?
|
| Humans | 27 | 2021 | 86645 | 0.290 |
Why?
|
| Carcinoma | 1 | 2010 | 436 | 0.280 |
Why?
|
| Ligands | 4 | 2017 | 433 | 0.280 |
Why?
|
| Models, Molecular | 4 | 2017 | 1286 | 0.260 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 2262 | 0.210 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2021 | 10 | 0.210 |
Why?
|
| Intestinal Perforation | 1 | 2021 | 34 | 0.210 |
Why?
|
| Prenylation | 1 | 2021 | 3 | 0.200 |
Why?
|
| Logistic Models | 3 | 2020 | 1187 | 0.190 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2013 | 138 | 0.190 |
Why?
|
| Injury Severity Score | 1 | 2020 | 111 | 0.180 |
Why?
|
| Cell Line | 3 | 2021 | 2468 | 0.180 |
Why?
|
| Wounds, Gunshot | 1 | 2021 | 72 | 0.180 |
Why?
|
| Thrombectomy | 1 | 2021 | 158 | 0.180 |
Why?
|
| Drainage | 1 | 2020 | 157 | 0.180 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 143 | 0.180 |
Why?
|
| Single Molecule Imaging | 1 | 2018 | 14 | 0.170 |
Why?
|
| Phosphatidylcholines | 1 | 2018 | 48 | 0.170 |
Why?
|
| Firearms | 1 | 2019 | 49 | 0.170 |
Why?
|
| Pneumonia | 1 | 2020 | 179 | 0.170 |
Why?
|
| Cricetulus | 1 | 2018 | 126 | 0.170 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2018 | 94 | 0.160 |
Why?
|
| Stents | 1 | 2021 | 377 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 243 | 0.160 |
Why?
|
| Thoracotomy | 1 | 2018 | 58 | 0.160 |
Why?
|
| Protein Isoforms | 1 | 2019 | 270 | 0.160 |
Why?
|
| Cricetinae | 1 | 2018 | 560 | 0.160 |
Why?
|
| Nanostructures | 1 | 2018 | 77 | 0.160 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 999 | 0.160 |
Why?
|
| Occupational Exposure | 1 | 2018 | 80 | 0.150 |
Why?
|
| Leukocyte Count | 1 | 2017 | 220 | 0.150 |
Why?
|
| Length of Stay | 1 | 2020 | 703 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 394 | 0.150 |
Why?
|
| Cyclic GMP-Dependent Protein Kinase Type II | 1 | 2016 | 2 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 2601 | 0.150 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 86 | 0.140 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2016 | 88 | 0.140 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 64 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 371 | 0.140 |
Why?
|
| Anions | 1 | 2016 | 31 | 0.140 |
Why?
|
| Allosteric Site | 2 | 2015 | 23 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 639 | 0.140 |
Why?
|
| Adult | 7 | 2020 | 25648 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 2360 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2017 | 268 | 0.130 |
Why?
|
| Algorithms | 2 | 2015 | 1830 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2017 | 464 | 0.130 |
Why?
|
| Amino Acid Sequence | 2 | 2017 | 2062 | 0.130 |
Why?
|
| Protein Interaction Mapping | 1 | 2015 | 82 | 0.130 |
Why?
|
| Molecular Probes | 1 | 2015 | 35 | 0.130 |
Why?
|
| Middle Aged | 6 | 2020 | 25028 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2020 | 4213 | 0.130 |
Why?
|
| Software | 2 | 2015 | 654 | 0.120 |
Why?
|
| Mutant Proteins | 3 | 2021 | 94 | 0.120 |
Why?
|
| Animals | 5 | 2021 | 26582 | 0.120 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 484 | 0.120 |
Why?
|
| Critical Illness | 2 | 2017 | 294 | 0.120 |
Why?
|
| Protein Structure, Secondary | 1 | 2015 | 330 | 0.120 |
Why?
|
| Male | 8 | 2021 | 40967 | 0.120 |
Why?
|
| Solutions | 1 | 2013 | 85 | 0.120 |
Why?
|
| United States | 3 | 2020 | 6674 | 0.110 |
Why?
|
| Opioid-Related Disorders | 1 | 2016 | 161 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2020 | 2262 | 0.110 |
Why?
|
| Peritoneal Lavage | 1 | 2012 | 10 | 0.110 |
Why?
|
| Sampling Studies | 1 | 2012 | 70 | 0.110 |
Why?
|
| Immunomodulation | 1 | 2012 | 55 | 0.110 |
Why?
|
| Evaluation Studies as Topic | 1 | 2012 | 274 | 0.110 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2012 | 121 | 0.110 |
Why?
|
| Bile Acids and Salts | 1 | 2012 | 61 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2013 | 110 | 0.100 |
Why?
|
| Physicians | 1 | 2019 | 673 | 0.100 |
Why?
|
| Nucleotides | 1 | 2012 | 95 | 0.100 |
Why?
|
| GTP-Binding Proteins | 1 | 2012 | 146 | 0.100 |
Why?
|
| Computer Simulation | 2 | 2015 | 1078 | 0.100 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 318 | 0.100 |
Why?
|
| Reference Values | 1 | 2012 | 674 | 0.100 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2011 | 21 | 0.100 |
Why?
|
| Urinary Catheterization | 1 | 2011 | 35 | 0.100 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2011 | 25 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2012 | 679 | 0.090 |
Why?
|
| Crystallography, X-Ray | 1 | 2012 | 485 | 0.090 |
Why?
|
| Water | 1 | 2012 | 277 | 0.090 |
Why?
|
| Iopamidol | 1 | 2010 | 10 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2012 | 912 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2012 | 839 | 0.090 |
Why?
|
| Radiography, Interventional | 1 | 2011 | 150 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2020 | 7993 | 0.090 |
Why?
|
| Female | 7 | 2020 | 44534 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2018 | 3241 | 0.090 |
Why?
|
| Radiopharmaceuticals | 1 | 2010 | 180 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2012 | 575 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 1075 | 0.080 |
Why?
|
| Radiography | 1 | 2010 | 813 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 1939 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2818 | 0.070 |
Why?
|
| Inflammation | 1 | 2012 | 920 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1313 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 6509 | 0.070 |
Why?
|
| Heart Failure | 1 | 2016 | 1204 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 744 | 0.070 |
Why?
|
| Neoplasms | 2 | 2019 | 2898 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 1991 | 0.060 |
Why?
|
| Lipids | 2 | 2016 | 269 | 0.060 |
Why?
|
| Contrast Media | 1 | 2010 | 1078 | 0.060 |
Why?
|
| Hospital Mortality | 2 | 2017 | 349 | 0.060 |
Why?
|
| Gastroenterostomy | 1 | 2021 | 7 | 0.050 |
Why?
|
| Endosonography | 1 | 2021 | 96 | 0.050 |
Why?
|
| Static Electricity | 1 | 2021 | 89 | 0.050 |
Why?
|
| Aged | 3 | 2016 | 18415 | 0.050 |
Why?
|
| Computed Tomography Angiography | 1 | 2021 | 131 | 0.040 |
Why?
|
| Politics | 1 | 2019 | 50 | 0.040 |
Why?
|
| Nanoparticles | 1 | 2021 | 157 | 0.040 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2019 | 60 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2019 | 78 | 0.040 |
Why?
|
| Cholesterol | 1 | 2021 | 356 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 567 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2019 | 339 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 94 | 0.040 |
Why?
|
| Health Surveys | 1 | 2018 | 239 | 0.040 |
Why?
|
| Neoprene | 1 | 2016 | 1 | 0.040 |
Why?
|
| Madin Darby Canine Kidney Cells | 1 | 2016 | 18 | 0.040 |
Why?
|
| Sildenafil Citrate | 1 | 2016 | 22 | 0.040 |
Why?
|
| Serine | 1 | 2016 | 99 | 0.040 |
Why?
|
| Hominidae | 1 | 2017 | 96 | 0.040 |
Why?
|
| Chicago | 1 | 2021 | 1379 | 0.030 |
Why?
|
| Health Personnel | 1 | 2018 | 202 | 0.030 |
Why?
|
| Endocytosis | 1 | 2016 | 177 | 0.030 |
Why?
|
| Dogs | 1 | 2016 | 685 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2015 | 46 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2015 | 71 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 752 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 860 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2016 | 278 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 859 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2015 | 103 | 0.030 |
Why?
|
| Adolescent | 2 | 2021 | 8982 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1197 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1718 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2017 | 8491 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 2426 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1578 | 0.020 |
Why?
|
| Hospitalization | 1 | 2016 | 849 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 3680 | 0.020 |
Why?
|
| Equipment Design | 1 | 2011 | 406 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2011 | 321 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 5417 | 0.020 |
Why?
|